We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

By LabMedica International staff writers
Posted on 03 Oct 2023
Print article
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations. Currently, the prostate-specific antigen (PSA) test is the standard method for initial screening. It measures PSA levels—a protein produced by the prostate—and higher levels often flag the need for further testing, like biopsies. The challenge is that elevated PSA levels could be due to various factors, like vigorous exercise or prostate infection, not just cancer. This can lead to unnecessary, invasive biopsies and treatments, which may have adverse side effects. To address this issue, a new blood diagnostic test has been developed to offer a risk score based on clinical and biological biomarkers that can help improve decision-making following a high PSA test result.

Nanostics (Edmonton, AB, Canada) has launched ClarityDX Prostate, a rapid, clinically validated diagnostic test that takes into account multiple factors, including PSA levels. It employs the ClarityDX machine learning platform to offer a more accurate risk score for aggressive prostate cancer. The test is designed to help patients and their healthcare providers decide if a biopsy is needed after getting a high PSA test result. It uses a unique machine-learning algorithm and examines data from two biological and three clinical biomarkers. Since it relies on lab data from an existing PSA blood test, it can be easily incorporated into the current patient care pathway at a low additional cost.

ClarityDX Prostate is particularly useful at the initial diagnosis stage to help decide whether a biopsy is necessary. Studies indicate that adding ClarityDX Prostate to the standard patient care path could reduce unnecessary biopsies by as much as 35%, leading to considerable cost savings. This groundbreaking blood test is a significant step forward in prostate cancer screening. It offers crucial support to men between the ages of 40 and 75 and their doctors in making more informed decisions—three times more accurately—about the need for a biopsy after a high PSA test result.

"This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk," said Dr. John D. Lewis, CEO of Nanostics.

Related Links:
Nanostics

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay
New
Tabletop Centrifuge
Mikro 185

Print article

Channels

Clinical Chemistry

view channel
Image: Rapid and non-invasive analysis of paracetamol overdose using paper arrow-mass spectrometry (Photo courtesy of Dr Simon Maher/University of Liverpool)

New Saliva Test Rapidly Identifies Paracetamol Overdose

Paracetamol is the most widely used medication worldwide, and its easy availability contributes to its frequent misuse and overdose. Overdosing on paracetamol can lead to liver toxicity, requiring hospitalization.... Read more

Hematology

view channel
Image: RHD screening just got easier with single exon NIPT testing (Photo courtesy of Devyser)

Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma

RhD (rhesus D) is a blood group type that can trigger immune responses. Individuals who lack RhD on their red blood cells are classified as RhD-negative. These individuals may produce antibodies against... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: A new test finds bacteria in liquids and indicate their presence by changing color (Photo courtesy of Georgia Kirkos/McMaster University)

New Hands-Free Rapid Test Detects Bacteria in Fluids

Bacteriophages, the most abundant form of life on Earth, are specialized to target and destroy specific types of bacteria. Their natural ability to fight bacteria has long been harnessed to treat infections.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.